Table 2 List of VIP VOMs obtained following PLS-DA analysis (score >1).

From: Exploring the potential of NTME/GC-MS, in the establishment of urinary volatomic profiles. Lung cancer patients as case study

VOMs

Comp. 1

Comp. 2

Comp. 3

Methyl chloride

1.10

1.03

1.00

Acetaldehyde

1.34

1.33

1.34

Carbon disulfide

1.34

1.25

1.21

Dimethyl sulfide

1.19

1.16

1.19

Acetone

0.86

0.92

1.00

2-Butanone

0.99

0.95

0.99

1,6-Dimethylhepta-1,3,5-triene

1.77

1.66

1.64

2,4-Dimethyl-3-pentanone

1.11

1.04

1.03

3,3-Dimethyl-6-methylenecyclohexene

1.64

1.52

1.50

Thiophene

1.09

1.10

1.10

3-Hexanone

1.17

1.18

1.18

Hexanal

1.02

0.96

0.96

2-Ethyl-5-methylfuran

1.17

1.14

1.11

2,2,6-Trimethyl-6-vinyltetrahydropyran

1.31

1.34

1.30

α-Phellandrene

1.73

1.64

1.61

α-Terpinene

1.56

1.52

1.49

1,4-Cineole

1.11

1.14

1.13

2-Heptanone

1.06

1.04

1.03

1-Ethyl-3-methylbenzene

1.60

1.49

1.48

Isoterpinolene

1.47

1.48

1.46

1,2,3-Trimethylbenzene

1.17

1.16

1.13

2,3-dihydro-1,1,5,6-tetramethyl-1H-indene

1.68

1.59

1.59

α-Curcumene

1.50

1.40

1.37

1,1,3-trimethyl-1H-indene

1.17

1.25

1.23

α-Calacorene

1.26

1.28

1.26

p-Cresol

1.65

1.56

1.52

Carvacrol

1.19

1.17

1.22

4-tert-Butylphenol

1.68

1.56

1.52

3,5-Di-t-butylphenol

2.16

2.21

2.15

  1. Comp. 1 – Component 1; Comp. 2 – Component 2; Comp. 3 – Component 3.